Schizophrenia drug MP-214 tested for Long-Term safety in 254 patients
NCT ID NCT01626872
First seen Jan 10, 2026 · Last updated May 08, 2026 · Updated 18 times
Summary
This study looked at the long-term safety and tolerability of the drug MP-214 in 254 adults with schizophrenia. Participants had already completed an earlier study and continued taking MP-214 to see how well it was tolerated over time. The main focus was on tracking any side effects or health issues that occurred.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site
Sapporo, Hokkaido, Japan
-
Study site
Seoul, South Korea
-
Study site
Taipei, Taiwan
Conditions
Explore the condition pages connected to this study.